Biotech Stocks Are A Bargain in Today’s Market

Bargain hunters should focus on biotechs since momentum is clearly on their side. On Wednesday, stocks closed higher, led by the small- and mid-cap sectors. The Nasdaq led all other indices, up 1%, while the S&P 500 rose 0.7% with 7 of 10 sectors advancing, and the Dow industrials gained 0.6%.

Retail sales for July were flat, but rather than this being interpreted as a negative, it was seen as a positive. With the economy posting mild growth and interest rates low, the Federal Reserve isn’t likely to jump ahead of the slow economy with an increase in interest rates.

Stocks have recently been impacted by conflict in Ukraine and the Middle East, but this week has been relatively calm. Retail stocks were hard hit following poor results from Macy’s (M), which was off 5.5%. Most of Wednesday’s gains were made in technology, with Apple (AAPL), Facebook (FB) and Google (GOOG) leading the group, and health care, which was led by biotech stocks.

Biotech Stock News

At the close, the Dow Jones Industrial Average rose 91 points to 16,651, the S&P 500 gained 13 points at 1,947, the Nasdaq jumped 45 points to 4,434, and the Russell 2000 gained 9 points at 1,142. Volume was very light on the NYSE’s primary market with just 550 million shares trading. The NYSE traded total volume of 2.7 billion shares, and the Nasdaq crossed 1.6 billion shares.

The Nasdaq finally breached its narrow trading range with a clean break above both its 50-day moving average at 4,389 and 20-day moving average at 4,408. The next objective is the twin top at 4,486. MACD flashed a new buy signal.

Biotech News Video

Watch this video for more “Biotech” news.

Biotech Financial News

Small-cap stocks, represented by the Russell 2000 (see Aug. 12 chart), are still pounding away at their 200-day moving average now at 1,145. Its MACD also flashed a buy signal, so perhaps it is only a matter of time before the little guys muster enough volume to break the barrier. However, even if they do manage to overcome the 200-day, there is much overhead (i.e., sellers waiting to pounce).

Thanks for visiting the website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone